

Sclerotherapy and Prolotherapy for Joints and Tendons

| Table of Content |
|---|
| Purpose |
| Description & Definitions |
| Criteria |
| Coding |
| Document History |
| References |
| Special Notes |
| Keywords |

| | |
|-------------------------|-------------|
| <u>Effective Date</u> | 9/2007 |
| <u>Next Review Date</u> | 9/15/2024 |
| <u>Coverage Policy</u> | Medical 108 |
| <u>Version</u> | 6 |

All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member’s condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*.

Purpose:

This policy addresses the medical necessity of Sclerotherapy and Prolotherapy for Joints and Tendons.

Description & Definitions:

Prolotherapy is injections into a site on the body to relieve pain.

Joint sclerotherapy is injecting a substance into a joint to produce an irritation to promote healing.

Reconstructive Ligament Therapy with Injections of Sclerosing Agents are injections into a site on the body to relieve pain.

Criteria:

Sclerotherapy and Prolotherapy for Joints and Tendons is considered **not medically necessary** for any indication.

Coding:

Medically necessary with criteria:

| Coding | Description |
|--------|-------------|
| | None |

Considered Not Medically Necessary:

| Coding | Description |
|--------|--------------|
| M0076 | Prolotherapy |

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

- 2021: February
- 2020: January
- 2015: March
- 2013: August
- 2012: August
- 2011: September
- 2010: December
- 2009: November

Reviewed Dates:

- 2023: August
- 2022: August
- 2020: November
- 2019: November
- 2018: October
- 2017: November
- 2016: July
- 2015: August
- 2014: August
- 2010: August, November
- 2009: August
- 2008: August

Effective Date:

- September 2007

References:

Including but not limited to: Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023). Retrieved July 13, 2023, from MCG 26th Edition: <https://careweb.careguidelines.com/ed26/index.html>

A Comprehensive Update of Prolotherapy in the Management of Osteoarthritis of the Knee. (2022, May 31). Retrieved July 13, 2023, from Orthopedic Reviews: <https://orthopedicreviews.openmedicalpublishing.org/article/33921-a-comprehensive-update-of-prolotherapy-in-the-management-of-osteoarthritis-of-the-knee>

Interventional Pain Management. (2023-04-09). Retrieved July 13, 2023, from Caelon Medical Benefits Management: <https://guidelines.caelonmedicalbenefitsmanagement.com/interventional-pain-management-2023-04-09/?highlight=Prolotherapy&hilit=Prolotherapy>

Local Coverage Determination (LCD) Trigger Point Injections L37635. (2020, Nov). Retrieved July 13, 2023, from Centers for Medicare and Medicaid Services LCD: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37635&ver=13&keyword=Prolotherapy&keywordType=starts&areald=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>

National Coverage Determination (NCD) Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents (150.7). (1999). Retrieved July 13, 2023, from Centers for Medicare & Medicaid Services NCD: <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=15&ncdver=1&keyword=Prolotherapy&keywordType=starts&areald=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>

Overview of the management of overuse (persistent) tendinopathy. (2021, June). Retrieved July 13, 2023, from UpToDate: https://www.uptodate.com/contents/overview-of-the-management-of-overuse-persistent-tendinopathy?search=Prolotherapy%20&source=search_result&selectedTitle=2~13&usage_type=default&display_rank=2#

Procedure Fee Files & CPT Codes. (2023). Retrieved July 13, 2023, from Department of Medical Assistance Services: <https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/> & <https://www.dmas.virginia.gov/for-providers/cardinal-care-transition/>

Prolotherapy. (2023, Mar 31). Retrieved July 13, 2023, from Cigna - EviCore: https://www.evicore.com/-/media/files/evicore/provider/network-standard/cigna-cmm-204-prolotherapy_v102023_final_pub02202023.pdf

Prolotherapy for Osteoarthritis. (2023). Retrieved July 13, 2023, from Arthritis Foundation: <https://www.arthritis.org/diseases/more-about/prolotherapy-for-osteoarthritis>

Prolotherapy For Treatment Of Joint And Ligamentous Conditions - ARCHIVED Sep 8, 2013. (n.d.). Retrieved July 13, 2023, from Hayes: <https://evidence.hayesinc.com/report/dir.scle0003>

Special Notes: *

This medical policy express Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to "correct or ameliorate" (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. *Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*

Keywords:

SHP Prolotherapy, SHP Medical 108, injections, pain relief, non-surgical ligament reconstruction, tendon reconstruction, joint pain